Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Elevated Hemoglobin A1C Predicts Myocardial Infarction after Mechanical Thrombectomy for Acute Ischemic Stroke
Cerebrovascular Disease and Interventional Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
4-002

To study the relationship between admission hemoglobin A1c (HbA1c) and outcomes in patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke (AIS).

Multiple randomized clinical trials have established EVT as the standard of care for large vessel occlusion (LVO) stroke. Recent literature suggests that elevated baseline HbA1c is associated with poor functional outcomes in AIS with or without IV alteplase; however, the effect of HbA1c on outcomes in patients undergoing EVT is unknown.

A retrospective cohort of 348 consecutive patients undergoing EVT at a large comprehensive stroke center was identified from February 2015 to September 2018. Sociodemographic, in-hospital treatment, complications and functional outcomes were collected through retrospective chart review. Multivariate regression model was used to adjust for confounding variables identified, using Chi square and Fisher exact test as appropriate.

Patient mean age was 71±14 years, 50.4% were female, 24% Black and 43% Hispanic. Median modified Rankin Scale (mRS) at baseline was 0 (IQR 0-1), median admission and 24 hour-post EVT NIHSS was 16 (IQR 11-20) and 12 (IQR 5-19), respectively. Overall, 33.6% of patients had a history of diabetes mellitus and mean HbA1C was 6.2±1.4. In multivariate analysis, higher HbA1c on admission was independently associated with myocardial infarction (MI) (OR 2.7, p 0.008) during hospitalization after EVT. There was a trend towards significance for higher admission NIHSS (OR 1.9, p 0.06), and acute kidney injury (AKI) (OR 1.7, p 0.09) for patients with elevated HbA1C. There was no significant difference in good functional outcomes (mRS 0-3) or inpatient mortality on multivariate regression.

Elevated hemoglobin A1C on admission in patients with LVO stroke requiring EVT is independently associated with higher incidence of MI during hospitalization and may be associated with more severe strokes. However, there was no significant difference in functional outcomes and in-hospital mortality based on HbA1C levels.

Authors/Disclosures
Juan Sebastian Diaz, MD (University of Miami, Dept of Neurology)
PRESENTER
No disclosure on file
Vasu Saini, MD Dr. Saini has nothing to disclose.
Nastajjia Krementz, MD (Vascular Neurology - University of Miami/Jackson Health System) Dr. Krementz has nothing to disclose.
Sishir Mannava, MD (UT Health) Dr. Mannava has nothing to disclose.
Melissa Bailey, MD Dr. Bailey has nothing to disclose.
Mario P. Zamora Dr. Zamora has nothing to disclose.
Daniel R. Kogan, MD (University of Miami/Jackson Memorial Hospital) No disclosure on file
Luis Guada-Delgado, MD (University of Miami) Dr. Guada-Delgado has nothing to disclose.
Elizabeth Jordan No disclosure on file
Nicole B. Sur, MD (University of Miami) Dr. Sur has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Sur has received research support from Florida Stroke Registry. The institution of Dr. Sur has received research support from Miami CTSI & NIH/NINDS.
Dileep R. Yavagal, MD, FÂé¶¹´«Ã½Ó³»­ (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.